




<u>LIST OF REFERENCE(S) CITED</u>				Atty. Docket No. R-0169B-REG		Serial No. 10/807,993	
				Applicants James Dunn, <i>et al.</i>			
				Filing Date March 23, 2004		Group 1624	
IDS No. 1							
U.S. PATENT DOCUMENTS							
Exam Initial	Ref. #	Document #	Date	Name	Class/ Subclass	Filing Date	
DR	A1	5,886,178	03/23/1999	Darin A. Allen, <i>et al.</i>			
FOREIGN PATENT DOCUMENTS							
	Ref.#	Document #	Publication Date	Country; Assignee	Language		
DR	B1	WO 96/24343-A1	08-15-1996	PCT, Smithkline Beecham Corp., U.S.			
DR	B2	WO 96/34851-A1	11-07-1996	PCT, Abbott Laboratories, U.S.			
DR	B3	WO 97/02023-A1	01-23-1997	PCT, Smithkline Beecham Corp., U.S.			
DR	B4	WO 97/02024-A1	01-23-1997	PCT, Smithkline Beecham Corp., U.S.			
DR	B5	WO 01/85670-A1	11-15-2001	PCT, Kissei Pharmaceutical Co., Ltd. (In Japanese w/ English Abstract)			
OTHER DOCUMENTS							
DR	C1	De CLERCQ, Erik, "New Developments in Anti-HIV Chemotherapy," <i>Current Medicinal Chemistry</i> , 2001, pp 1543-1572, vol. 8. No. 13.					
DR	C2	LEESON, Paul D., "Selective Thyromimetics. Cardiac-Sparing Thyroid Hormone Analogues Containing 3'-Arylmethyl Substituents," <i>J. Med. Chem.</i> , 1989, pp. 320-336, vol. 32, no.2.					
DR	C3	BUCKHEIT, Jr., Robert W., "Non-nucleoside reverse transcriptase inhibitors: perspectives on novel therapeutic compounds and strategies for the treatment of HIV infection," <i>Expert Opin. Investig. Drugs</i> , Ashley Publications Ltd., 2001, pp. 1423-1442, vol. 10, no. 8.					
EXAMINER /Deepak Rao/				DATE CONSIDERED 06/12/2006			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							



PTO/SB/08a (08-03)

Approved for use through 07/31/2008. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

of

Complete if Known

Application Number	10/807,993
Filing Date	March 23, 2004
First Named Inventor	James Patrick Dunn, et al
Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	R0169B-REG

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
DR	B1	Chintakunta, V.K., et al, "3-O-Substituted benzyl pyridazinone derivatives as COX inhibitors", <i>Eur. J. Med. Chem.</i> , 2004 <u>37</u> (4):339-347, <u>2002</u>	

Examiner
Signature

/Deepak Rao/

Date
Considered

06/12/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.** Doc. #125387v1